Skip to content
Pharma Observatory a Scientist.com platform

Clinical trial

Prospective Multicentre Phase II Study to Evaluate the Combination of Rituximab and DepoCyte® by Intrathecal Injection in the C5R Chemotherapy Protocol in Patients Between the Ages of 18 and 60 Years With Primary Cerebral Non-Hodgkin Lymphoma and Systemic Diffuse Large B-cell Lymphoma With Neuromeningeal Invasion at Diagnosis

NCT00553943 is registered in ClinicalTrials.gov with Lymphoma Study Association as lead sponsor.

NCT NCT00553943
Email me this page as a PDF

Search trials, sites, companies and investigators, and follow each one to the others. Individual plan, $249/seat/mo. Card required.

Get the NCT00553943 report as a PDF

The PDF carries up to 50 rows of each section, where the page shows the first few, with the sources listed. Enter a work email and confirm it from the message we send, and the report follows by email.

Registry record

As filed in ClinicalTrials.gov.

Title
Prospective Multicentre Phase II Study to Evaluate the Combination of Rituximab and DepoCyte® by Intrathecal Injection in the C5R Chemotherapy Protocol in Patients Between the Ages of 18 and 60 Years With Primary Cerebral Non-Hodgkin Lymphoma and Systemic Diffuse Large B-cell Lymphoma With Neuromeningeal Invasion at Diagnosis
Lead sponsor
Lymphoma Study Association
Phase
Phase 2
Overall status
Completed
Start date
July 31, 2007
Completion date
March 31, 2017
Enrollment
60 (actual)
Sites
46

Conditions

As the registry lists them; a condition with its own page is linked.

diffuse large b-cell lymphoma, lymphoma, non-hodgkin